An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

Inclusion criteria: participants with: * A minimum bilateral nasal polyp score of 5 out of a maximum score of 8 (with a unilateral score of at least 2 for each nostril) despite completion of a prior intranasal corticosteroid (INCS) treatment for at least 8 weeks before screening. * Presence of at least two of the following symptoms prior to screening: nasal blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); facial pain/pressure; reduction or loss of smell. Exclusion criteria: * Participants \<18 or \>65 years of age. * Sinonasal outcome test (SNOT-22) \<7. * Participants who had taken other investigational drugs or prohibited therapy for this study within 2 months before screening or 5 half-lives, whichever was longer: * Burst of systemic corticosteroids within the 2 months before screening or were scheduled to receive systemic corticosteroids during the study period for another condition * INCS drops within 1 month prior to screening * Monoclonal antibody (mAB) and immunosuppressive treatment * Anti-immunoglobulin E (IgE) therapy (omalizumab) within 130 days of Visit 1 * Leukotriene antagonists/modifiers unless participant was on a continuous treatment for at least 30 days prior to Visit 1. * Participants who had undergone any nasal surgery (including polypectomy) within 6 months before screening or have had more than 5 sinonasal surgeries in the past of which maximal 2 were surgeries changing the lateral wall structure of the n…